These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 11875628

  • 1. Time-dependent induction of anxiogenic-like effects after central infusion of urocortin or corticotropin-releasing factor in the rat.
    Spina MG, Merlo-Pich E, Akwa Y, Balducci C, Basso AM, Zorrilla EP, Britton KT, Rivier J, Vale WW, Koob GF.
    Psychopharmacology (Berl); 2002 Mar; 160(2):113-21. PubMed ID: 11875628
    [Abstract] [Full Text] [Related]

  • 2. Differential monoaminergic, neuroendocrine and behavioural responses after central administration of corticotropin-releasing factor receptor type 1 and type 2 agonists.
    de Groote L, Peñalva RG, Flachskamm C, Reul JM, Linthorst AC.
    J Neurochem; 2005 Jul; 94(1):45-56. PubMed ID: 15953348
    [Abstract] [Full Text] [Related]

  • 3. A study of the lasting effects of cocaine pre-exposure on anxiety-like behaviors under baseline conditions and in response to central injections of corticotropin-releasing factor.
    Erb S, Kayyali H, Romero K.
    Pharmacol Biochem Behav; 2006 Sep; 85(1):206-13. PubMed ID: 16987545
    [Abstract] [Full Text] [Related]

  • 4. Human urocortin 2, a corticotropin-releasing factor (CRF)2 agonist, and ovine CRF, a CRF1 agonist, differentially alter feeding and motor activity.
    Zorrilla EP, Reinhardt LE, Valdez GR, Inoue K, Rivier JE, Vale WW, Koob GF.
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1027-34. PubMed ID: 15115804
    [Abstract] [Full Text] [Related]

  • 5. Effects of urocortin 2 and 3 on motor activity and food intake in rats.
    Ohata H, Shibasaki T.
    Peptides; 2004 Oct; 25(10):1703-9. PubMed ID: 15476937
    [Abstract] [Full Text] [Related]

  • 6. Increased ethanol self-administration and anxiety-like behavior during acute ethanol withdrawal and protracted abstinence: regulation by corticotropin-releasing factor.
    Valdez GR, Roberts AJ, Chan K, Davis H, Brennan M, Zorrilla EP, Koob GF.
    Alcohol Clin Exp Res; 2002 Oct; 26(10):1494-501. PubMed ID: 12394282
    [Abstract] [Full Text] [Related]

  • 7. Stress and central Urocortin increase anxiety-like behavior in the social interaction test via the CRF1 receptor.
    Gehlert DR, Shekhar A, Morin SM, Hipskind PA, Zink C, Gackenheimer SL, Shaw J, Fitz SD, Sajdyk TJ.
    Eur J Pharmacol; 2005 Feb 21; 509(2-3):145-53. PubMed ID: 15733549
    [Abstract] [Full Text] [Related]

  • 8. Corticotropin-releasing factor (CRF)-induced behaviors are modulated by intravenous administration of teneurin C-terminal associated peptide-1 (TCAP-1).
    Al Chawaf A, Xu K, Tan L, Vaccarino FJ, Lovejoy DA, Rotzinger S.
    Peptides; 2007 Jul 21; 28(7):1406-15. PubMed ID: 17644218
    [Abstract] [Full Text] [Related]

  • 9. Effects of ovine CRF injections into the dorsomedial, dorsolateral and lateral columns of the periaqueductal gray: a functional role for the dorsomedial column.
    Borelli KG, Brandão ML.
    Horm Behav; 2008 Jan 21; 53(1):40-50. PubMed ID: 17920596
    [Abstract] [Full Text] [Related]

  • 10. Effect of a benzodiazepine receptor agonist and corticotropin-releasing hormone receptor antagonists on long-term foot-shock-induced increase in defensive withdrawal behavior.
    Bruijnzeel AW, Stam R, Wiegant VM.
    Psychopharmacology (Berl); 2001 Nov 21; 158(2):132-9. PubMed ID: 11702086
    [Abstract] [Full Text] [Related]

  • 11. Antidepressant-like effects of the CRF family peptides, urocortin 1, urocortin 2 and urocortin 3 in a modified forced swimming test in mice.
    Tanaka M, Telegdy G.
    Brain Res Bull; 2008 Mar 28; 75(5):509-12. PubMed ID: 18355626
    [Abstract] [Full Text] [Related]

  • 12. Differential dose effects of central CRF and effects of CRF astressin on pig behavior.
    Salak-Johnson JL, Anderson DL, McGlone JJ.
    Physiol Behav; 2004 Oct 30; 83(1):143-50. PubMed ID: 15501501
    [Abstract] [Full Text] [Related]

  • 13. Participation of corticotropin-releasing factor type 2 receptors in the acute, chronic and withdrawal actions of nicotine associated with feeding behavior in rats.
    Kamdi SP, Nakhate KT, Dandekar MP, Kokare DM, Subhedar NK.
    Appetite; 2009 Dec 30; 53(3):354-62. PubMed ID: 19635511
    [Abstract] [Full Text] [Related]

  • 14. Anxiogenic and antinociceptive effects induced by corticotropin-releasing factor (CRF) injections into the periaqueductal gray are modulated by CRF1 receptor in mice.
    Miguel TT, Nunes-de-Souza RL.
    Horm Behav; 2011 Aug 30; 60(3):292-300. PubMed ID: 21723867
    [Abstract] [Full Text] [Related]

  • 15. Analysis of the anxiolytic-like effect of TRH and the response of amygdalar TRHergic neurons in anxiety.
    Gutiérrez-Mariscal M, de Gortari P, López-Rubalcava C, Martínez A, Joseph-Bravo P.
    Psychoneuroendocrinology; 2008 Feb 30; 33(2):198-213. PubMed ID: 18079066
    [Abstract] [Full Text] [Related]

  • 16. Urocortin 2 acts centrally to delay gastric emptying through sympathetic pathways while CRF and urocortin 1 inhibitory actions are vagal dependent in rats.
    Czimmer J, Million M, Taché Y.
    Am J Physiol Gastrointest Liver Physiol; 2006 Mar 30; 290(3):G511-8. PubMed ID: 16223946
    [Abstract] [Full Text] [Related]

  • 17. Astressin, a corticotropin releasing factor antagonist, reverses the anxiogenic effects of urocortin when administered into the basolateral amygdala.
    Sajdyk TJ, Gehlert DR.
    Brain Res; 2000 Sep 22; 877(2):226-34. PubMed ID: 10986336
    [Abstract] [Full Text] [Related]

  • 18. Repeated intracerebral teneurin C-terminal associated peptide (TCAP)-1 injections produce enduring changes in behavioral responses to corticotropin-releasing factor (CRF) in rat models of anxiety.
    Tan LA, Xu K, Vaccarino FJ, Lovejoy DA, Rotzinger S.
    Behav Brain Res; 2008 Mar 17; 188(1):195-200. PubMed ID: 18082275
    [Abstract] [Full Text] [Related]

  • 19. Injections of urocortin 1 into the basolateral amygdala induce anxiety-like behavior and c-Fos expression in brainstem serotonergic neurons.
    Spiga F, Lightman SL, Shekhar A, Lowry CA.
    Neuroscience; 2006 Mar 17; 138(4):1265-76. PubMed ID: 16488545
    [Abstract] [Full Text] [Related]

  • 20. Neonatal thyroxine treatment: changes in the number of corticotropin-releasing-factor (CRF) and neuropeptide Y (NPY) containing neurons and density of tyrosine hydroxylase positive fibers (TH) in the amygdala correlate with anxiety-related behavior of wistar rats.
    Yilmazer-Hanke DM, Hantsch M, Hanke J, Schulz C, Faber-Zuschratter H, Schwegler H.
    Neuroscience; 2004 Mar 17; 124(2):283-97. PubMed ID: 14980379
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.